Pardes Biosciences Announces Commencement of Phase II Trial Evaluating PBI-0451 for the Treatment of SARS-CoV-2 Infections

Pardes Biosciences, Inc. reported commencement of a Phase II double-blind, randomized study to evaluate the antiviral activity, safety, and efficacy of orally administered PBI-0451 compared with placebo in non-hospitalized symptomatic adults with COVID-19 who are not at increased risk of progressing to severe illness.